medline.ch Onkologie Urologische Tumoren

	Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications. Biochim Biophys Acta Rev Cancer Carpenter VJ, Patel BB, Autorino R, Smith SC, Gewirtz DA, Saleh T. PMID: 32956765 [PubMed - as supplied by publisher]
	Transperineal versus transrectal targeted biopsy with use of electromagnetically-tracked MR/US fusion guidance platform for the detection of clinically significant prostate cancer. Urology Winoker JS, Wajswol E, Falagario U, Maritini A, Moshier E, Voutsinas N, Knauer CJ, Sfakianos JP, Lewis SC, Taouli BA, Rastinehad AR. PMID: 32956688 [PubMed - as supplied by publisher]
	Sudden PSA rise to â‰¥20 ng/ml and prostate cancer diagnosis in the United States: A population-based study. Prostate Vilson FL, Li S, Brooks JD, Eisenberg ML. PMID: 32956488 [PubMed - as supplied by publisher]
	Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis. Clin Nucl Med Satapathy S, Mittal BR, Sood A. PMID: 32956129 [PubMed - as supplied by publisher]
	The utility of a deep learning-based algorithm for bone scintigraphy in patient with prostate cancer. Ann Nucl Med Aoki Y, Nakayama M, Nomura K, Tomita Y, Nakajima K, Yamashina M, Okizaki A. PMID: 32955663 [PubMed - as supplied by publisher]
	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüro, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J, PROfound Trial Investigators.. PMID: 32955174 [PubMed - as supplied by publisher]
	Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients. Biomed Res Int Cai J, Chen Z, Chen X, Huang H, Lin X, Miao B. PMID: 32953881 [PubMed - in process]
	Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Ann Transl Med Westerman ME, Wood CG. PMID: 32953837 [PubMed]
	Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol Handa S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A. PMID: 32952615 [PubMed]
	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. Eur Urol Oncol Rocco B, Sighinolfi MC, Sandri M, Spandri V, Cimadamore A, Volavsek M, Mazzucchelli R, Lopez-Beltran A, Eissa A, Bertoni L, Azzoni P, Reggiani Bonetti L, Maiorana A, Puliatti S, Micali S, Paterlini M, Iseppi A, Rocco F, Pellacani G, Chester J, Bianchi G, Montironi R. PMID: 32952095 [PubMed - as supplied by publisher]
	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urol Oncol Goldberg H, Mohsin FK, Berlin A, Chandrasekar T, Wallis CJD, Klaassen Z, Ahmad AE, Saskin R, Kenk M, Saarela O, Kulkarni GS, Alibhai SMH, Fleshner N. PMID: 32951988 [PubMed - as supplied by publisher]
	Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Int J Clin Pharm Wu YH, Jhan JH, Ke HL, Tseng SI, Chang YH, Yeh HC, Li CC, Lee YC. PMID: 32951178 [PubMed - as supplied by publisher]
	Simple low-cost approaches to semantic segmentation in radiation therapy planning for prostate cancer using deep learning with non-contrast planning CT images. Phys Med Nemoto T, Futakami N, Yagi M, Kunieda E, Akiba T, Takeda A, Shigematsu N. PMID: 32950833 [PubMed - as supplied by publisher]
	Second line salvage systemic therapy for advanced penile cancer. Urol Oncol Chahoud J, Tamil M, Necchi A. PMID: 32950396 [PubMed - as supplied by publisher]
	Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N. PMID: 32949550 [PubMed - as supplied by publisher]
	Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate Harshman LC, Wang VX, Hamid AA, Santone G, Drake CG, Carducci MA, DiPaola RS, Fichorova RN, Sweeney CJ. PMID: 32949185 [PubMed - as supplied by publisher]
	Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of ⁶⁸Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer. Abdom Radiol (NY) Zou Q, Jiao J, Zou MH, Li MZ, Yang T, Xu L, Zhang Y. PMID: 32948911 [PubMed - as supplied by publisher]
	A cohort study among 402 patients with penile cancer in MaranhÃ£o, Northeast Brazil with the highest worldwide incidence. BMC Res Notes Vieira CB, Teixeira-Júnior A, Feitoza L, Pinho J, Calixto J, do Nascimento FSMS, Campos MAG, Lages J, Junior AMA, Soares F, Cunha I, Silva GEB. PMID: 32948228 [PubMed - in process]
	Survival outcomes in men with a positive family history of prostate cancer: a registry based study. BMC Cancer Ang M, Borg M, O'Callaghan ME, South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC).. PMID: 32948129 [PubMed - in process]
	The Role of Imaging in Bladder Cancer Diagnosis and Staging. Diagnostics (Basel) Galgano SJ, Porter KK, Burgan C, Rais-Bahrami S. PMID: 32948089 [PubMed]

Artikel 1 - 20 / 130331

Seite 1 von 6517

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung